2026-05-12T10:42:40Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/ojh.000004 2020-11-23 PTZ.OJH:VOL2

Advances in Cholangiocarcinoma Treatment in the Personalized Medicine Era Kathrin Dvir Gliceida M Galarza Fortuna Nathaly Cortez Veronica GuerraMike Cusnir<p>Cholangiocarcinoma is amongst the most common primary tumors of the liver, second only to hepatocellular carcinoma, and it accounts for approximately 15% of primary hepatic malignancies [1]. Cholangiocarcinoma is sub-classified as intrahepatic (ICCA), perihilar (PCCA) or distal (DCCA), according to its anatomical location [2]. Regardless of location, cholangiocarcinoma carries a poor prognosis, mainly due to paucity of effective therapy options and advanced disease at presentation. The American Cancer Society determined a 5-year relative survival rate of 8% for all patients with intrahepatic bile duct cancer and 10% for its extrahepatic counterpart. Even localized disease carries poor survival of 24% and 15% for ICCA and extrahepatic cholangiocarcinoma, respectively [3].&nbsp;</p><p><br></p> Open Journal of Hepatology - Peertechz Publications 2020-11-23 Mini Review https://doi.org/10.17352/ojh.000004 en Copyright © Kathrin Dvir et al.